Ekso Bionics Holdings, Inc. (EKSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

3.0800

-0.1300

(-4.05%)

As of 12:21PM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	3.2100
Open	3.2300
Bid	3.0300 x 2200
Ask	3.0400 x 1200
Day's Range	3.0200 - 3.2300
52 Week Range	3.0200 - 14.9800
Volume	70,224
Avg. Volume	124,761

Market Cap	39.004M
Beta (5Y Monthly)	1.92
PE Ratio (TTM)	N/A
EPS (TTM)	-1.0110
Earnings Date	Feb 23, 2022 - Feb 28, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	11.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EKSO

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Ekso Bionics Holdings, Inc.
Analyst Report: Zimmer Biomet Holdings, Inc.Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Close to 60% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products; the remaining portion is primarily related to spine and dental products.
Rating
Fair Value
Economic Moat
6 days agoMorningstar

All

News

Press Releases

Research Reports

Zacks
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 32.00% and 18.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Ekso Bionics Reports Third Quarter 2021 Results
RICHMOND, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2021. Recent Highlights and Accomplishments Reported revenue of $3.0 million in the third quarter of 2021Achieved gross margin of approximately 59% in the third quarter of 2021Booked a total of 16 EksoNR units in the third quarter of 202
GlobeNewswire
Ekso Bionics to Report Third Quarter 2021 Financial Results on November 2, 2021
RICHMOND, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2021 after the close of trading on Tuesday, November 2, 2021. Management will host a conference call beginning at 1:30 p.m. PT, 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcas